Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • بيانات النشر:
      Radiological Society of North America
      Faculty of Medicine and Health, Sydney School of Public Health
    • الموضوع:
      2021
    • Collection:
      The University of Sydney: Sydney eScholarship Repository
    • نبذة مختصرة :
      Background Since 2007, digital mammography and digital breast tomosynthesis (DBT) replaced screen-film mammography. Whether these technologic advances have improved diagnostic performance has, to the knowledge of the authors, not yet been established. Purpose To evaluate the performance and outcomes of surveillance mammography (digital mammography and DBT) performed from 2007 to 2016 in women with a personal history of breast cancer and compare with data from 1996 to 2007 and the performance of digital mammography screening benchmarks. Materials and Methods In this observational cohort study, five Breast Cancer Surveillance Consortium registries provided prospectively collected mammography data linked with tumor registry and pathologic outcomes. This study identified asymptomatic women with American Joint Committee on Cancer anatomic stages 0-III primary breast cancer who underwent surveillance mammography from 2007 to 2016. The primary outcome was a second breast cancer diagnosis within 1 year of mammography. Performance measures included the recall rate, cancer detection rate, interval cancer rate, positive predictive value of biopsy recommendation, sensitivity, and specificity. Results Among 32 331 women who underwent 117 971 surveillance mammographic examinations (112 269 digital mammographic examinations and 5702 DBT examinations), the mean age at initial diagnosis was 59 years ± 12 (standard deviation). Of 1418 second breast cancers diagnosed, 998 were surveillance-detected cancers and 420 were interval cancers. The recall rate was 8.8% (10 365 of 117 971; 95% CI: 8.6%, 9.0%), the cancer detection rate was 8.5 per 1000 examinations (998 of 117 971; 95% CI: 8.0, 9.0), the interval cancer rate was 3.6 per 1000 examinations (420 of 117 971; 95% CI: 3.2, 3.9), the positive predictive value of biopsy recommendation was 31.0% (998 of 3220; 95% CI: 29.4%, 32.7%), the sensitivity was 70.4% (998 of 1418; 95% CI: 67.9%, 72.7%), and the specificity was 98.1% (114 331 of 116 553; 95% CI: 98.0%, 98.2%). Compared with ...
    • File Description:
      application/pdf
    • Relation:
      National Cancer Institute (P01CA154292, U54CA163303); Patient-Centered Outcomes Research Institute (PCS-1504-30370); National Cancer Institute (R50CA211115); National Breast Cancer Foundation (Australia) Research Leadership Fellowship; https://hdl.handle.net/2123/30155
    • الرقم المعرف:
      10.1148/radiol.2021204581
    • الدخول الالكتروني :
      https://hdl.handle.net/2123/30155
      https://doi.org/10.1148/radiol.2021204581
    • Rights:
      Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
    • الرقم المعرف:
      edsbas.AC3A5890